Treatment of Viral Encephalitis in B Virus Encephalitis

Viral encephalitis in the context of B virus infection is a distinct and serious clinical scenario. CNS involvement is a key factor that directly influences agent selection and duration of treatment.

Clinical Scenario

Viral encephalitis attributable to B virus — a presentation in which prompt antiviral treatment is indicated, with specific considerations when central nervous system symptoms are present.

Treatment Approach

Antiviral therapy is recommended for B virus encephalitis, with an oral agent as the preferred first-line option and intravenous alternatives available for specific clinical circumstances. The complete regimen — including agent selection, duration, and sequencing — is detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1086/589747

B virus: valacyclovir is recommended (B-III); alternative agents are ganciclovir (B-III) and acyclovir (C-III).

Valacyclovir (1 g orally every 8 h) is recommended because higher serum concentrations can be achieved.

Some experts recommend ganciclovir (5 mg/kg intravenously every 12 h for a minimum of 14 days or until all CNS symptoms have resolved) if the CNS is involved; subsequent administration of valacyclovir for suppression of latent infection may also be considered.

Acyclovir (12.5–15 mg/kg intravenously every 8 h) has been suggested for acute infection; case reports in patients with B virus encephalitis have demonstrated full recovery, although the efficacy of this approach has not been systematically examined.

View source ↗